Risk-benefit analysis of isoniazid monotherapy to prevent tuberculosis in patients with rheumatic diseases exposed to prolonged, high-dose glucocorticoids.
Jun Won ParkJeffrey R CurtisHajeong LeeJung-Kyu LeeYeong Wook SongEun Bong LeePublished in: PloS one (2020)
INH treatment to prevent TB might be effective in high-risk patients but has a risk of frequent ADRs, which limits its use in general practice in patients not at a high risk of developing TB.
Keyphrases
- end stage renal disease
- mycobacterium tuberculosis
- general practice
- ejection fraction
- chronic kidney disease
- high dose
- newly diagnosed
- prognostic factors
- randomized controlled trial
- peritoneal dialysis
- emergency department
- patient reported outcomes
- combination therapy
- hiv aids
- study protocol
- stem cell transplantation
- electronic health record
- replacement therapy